Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C, Chronic

Explore clinical trials studying Hepatitis C, Chronic. Study availability and eligibility vary by location and protocol.

314 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C, Chronic trial results

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

NCT00483938

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Milwaukee, Wisconsin, United States
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Edmonton, Alberta, Canada
View all 23 locations
View Trial Details
Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

NCT00377182

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
View all 18 locations
View Trial Details
Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • La Jolla, California, United States
  • Sacramento, California, United States
  • Orlando, Florida, United States
  • Marietta, Georgia, United States
View all 32 locations
View Trial Details
Completed

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

NCT00963885

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Phoenix, Arizona, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
View all 43 locations
View Trial Details
Completed

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

NCT01628094

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • La Jolla, California, United States
  • Englewood, Colorado, United States
  • South Miami, Florida, United States
  • Marietta, Georgia, United States
View all 31 locations
View Trial Details
Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

NCT01750216

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Bydgoszcz, Poland
  • Bytom, Poland
  • Chorzów, Poland
  • Ciechanów, Poland
View all 14 locations
View Trial Details

Related conditions